A
Arrowhead Pharmaceuticals, Inc. (ARWR)
NMS – Real vaqt narxi. Valyuta: USD
79.04
+1.30 (1.67%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
79.04
+1.30 (1.67%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Arrowhead Pharmaceuticals, Inc. Qo'shma Shtatlarda davolab bo'lmaydigan kasalliklarni davolash uchun dori vositalarini ishlab chiqadi. Uning portfelida 3-bosqich tadqiqotlarida apolipoprotein C-III ishlab chiqarishni kamaytirish uchun Plozasiran; 3-bosqich klinik sinovlarida angiopoietin-like protein 3 ishlab chiqarishni kamaytirish uchun Zodasiran; 1/2a bosqich klinik sinovlarida ikki tomonlama funktsional RNAi molekulasi ARO-DIMER-PA; va 1-bosqich klinik sinovlarida tadqiq qilinayotgan RNAi terapiyasi ARO-PNPLA3 mavjud. Kompaniya, shuningdek, 1/2a bosqich klinik sinovlarida INHBE genining va uning sekretsiya qilinadigan gen mahsuloti, Activin E ning jigar orqali ifodalanishini kamaytirish uchun ARO-INHBE; 1/2a bosqich klinik sinovlarida ACVR1C genining adipotsitlar orqali ifodalanishini bostirish uchun ARO-ALK7; 1/2a bosqich klinik sinovlarida ilg'or glyukatsiyalangan mahsulotlar retseptorining ishlab chiqarishini kamaytirish uchun ARO-RAGE; va tadqiq qilinayotgan RNAi asosidagi terapiya ARO-MAPTni ishlab chiqadi. Bundan tashqari, u 1/2a bosqich klinik sinovlarida C3 ishlab chiqarishni kamaytirish uchun ARO-C3; va 1/2a bosqich klinik sinovlarida CFB ning jigardagi ifodalanishini kamaytirish uchun ARO-CFB ni ishlab chiqmoqda. Kompaniya Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; va Sarepta Therapeutics, Inc. bilan hamkorlik va litsenziyalash shartnomalariga ega. Arrowhead Pharmaceuticals, Inc. 2003 yilda tashkil etilgan va shtab-kvartirasi Pasadena, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Aaron Tan | Head of Tax |
| Dr. Bruce D. Given M.D. | Chief Medical Scientist |
| Dr. Christopher R. Anzalone Ph.D. | Chairman, CEO & President |
| Dr. James C. Hamilton M.D., MBA | Chief Medical Officer and Head of R&D |
| Dr. Mark Seefeld | Head of Toxicology & VP |
| Dr. Mark M. Davis Ph.D. | Founder and Founder & Director of Insert Therapeutics Inc & Calando |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | S-8 | d30467ds8.htm |
| 2026-03-20 | 8-K | arwr-20260319.htm |
| 2026-02-05 | 8-K | arwr-20260205.htm |
| 2026-01-27 | DEFA14A | noiticeandfilingtext.htm |
| 2026-01-12 | 8-K | d19865d8k.htm |
| 2026-01-09 | 8-K | d94918d8k.htm |
| 2026-01-08 | 305B2 | d874243d305b2.htm |
| 2026-01-06 | 8-K | arwr-20260106.htm |
| 2025-12-11 | S-3ASR | d16145ds3asr.htm |
| 2025-11-25 | 10-K | arwr-20250930.htm |
| Dr. Tao Pei Ph.D. | Chief Scientific Officer |
| Dr. Vincent Anzalone CFA | Head of Investor Relations & VP |
| Mr. Daniel J. Apel | Chief Financial Officer |
| Mr. Howard Lovy | Director of Communications |